236 related articles for article (PubMed ID: 36078082)
1. miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
de la Cruz-Ojeda P; Schmid T; Boix L; Moreno M; Sapena V; Praena-Fernández JM; Castell FJ; Falcón-Pérez JM; Reig M; Brüne B; Gómez-Bravo MA; Giráldez Á; Bruix J; Ferrer MT; Muntané J
Cells; 2022 Aug; 11(17):. PubMed ID: 36078082
[TBL] [Abstract][Full Text] [Related]
2. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
3. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
Shao YY; Chen PS; Lin LI; Lee BS; Ling A; Cheng AL; Hsu C; Ou DL
Br J Cancer; 2022 Jun; 126(12):1806-1814. PubMed ID: 35236936
[TBL] [Abstract][Full Text] [Related]
4. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
Zhang Y; Pan Q; Shao Z
Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
[TBL] [Abstract][Full Text] [Related]
6. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1.
Li Y; Bai W; Zhang J
Biomed Pharmacother; 2017 Aug; 92():1038-1044. PubMed ID: 28609841
[TBL] [Abstract][Full Text] [Related]
7. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
9. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
10. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Vaira V; Roncalli M; Carnaghi C; Faversani A; Maggioni M; Augello C; Rimassa L; Pressiani T; Spagnuolo G; Di Tommaso L; Fagiuoli S; Rota Caremoli E; Barberis M; Labianca R; Santoro A; Bosari S
Liver Int; 2015 Mar; 35(3):1077-86. PubMed ID: 25040368
[TBL] [Abstract][Full Text] [Related]
12. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
13. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
15. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
[TBL] [Abstract][Full Text] [Related]
16. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Lu Y; Chan YT; Wu J; Feng Z; Yuan H; Li Q; Xing T; Xu L; Zhang C; Tan HY; Lee TK; Feng Y; Wang N
Drug Resist Updat; 2023 Nov; 71():101015. PubMed ID: 37924725
[TBL] [Abstract][Full Text] [Related]
18. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
Guo XL; Wang HB; Yong JK; Zhong J; Li QH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
[TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
20. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma.
Bergamini C; Leoni I; Rizzardi N; Melli M; Galvani G; Coada CA; Giovannini C; Monti E; Liparulo I; Valenti F; Ferracin M; Ravaioli M; Cescon M; Vasuri F; Piscaglia F; Negrini M; Stefanelli C; Fato R; Gramantieri L; Fornari F
J Exp Clin Cancer Res; 2023 Jun; 42(1):145. PubMed ID: 37301960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
